logo-loader
viewScancell Holdings PLC

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform

word patent spelled out in building blocks
The company is looking to extent patent protection internationally

Scancell Holdings PLC (LON:SCLP) said the European Patent Office has "granted broad protection" for the company's Moditope immunotherapy platform, which comes into effect from June 13.

It covers the company's pipeline of Moditope-derived vaccines. Counterparts to thpatent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US, the firm added.

"This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins," said chief scietific officer,  Professor Lindy Durrant.

Well positioned

"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard-to-treat cancers including ovarian, triple negative breast cancer and sarcoma."

First-in-man trials with Modi-1, which combines Moditope peptides with an ultra-efficient substance called an adjuvant that enhances the body's immune response, are due to start in the first half of next year.

 

Quick facts: Scancell Holdings PLC

Price: 4.9 GBX

LSE:SCLP
Market: LSE
Market Cap: £22.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read